Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Design AP7 Rec'd PCT/PTO 11 JUL 2005."

Approved for use through 3/31/2007. OMB 0651-0021

Approved for use through 3/31/2007. Olv	15 0031-0021							
U. S. PATI U.S.	ATTORNEY'S DOCKET NUMBER							
·	21581YP 							
TRANSMITTAL LETTER DESIGNATED/ELECTE CONCERNING A FILIN	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/585603							
INTERNATIONAL APPLICATION NO.		PRIORITY DATE CLAIMED						
PCT/US2005/000951	12 January 2005	16 January 2004						
TITLE OF INVENTION NOVEL CRYSTALLINE SALTS OF	A DIPEPTIDYL PEPTIDASE-IV INF	HIBITOR						
APPLICANT(S) FOR DO/EO/US								
Russell R. Ferlita, Karl Hansen, Vicky K. Vydra, Yaling Wang, Christopher M. Lindemann								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. X This is a FIRST submission	of items concerning a filing under 35 U	J.S.C. 371.						
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.								
·								
5. A copy of the International Application as filed [35 U.S.C. 371(c)(2)]								
a. is attached hereto (required only if not communicated by the International Bureau).								
b. has been communicated by the International Bureau.								
c. X is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. a. is attached hereto								
b. has been previously submitted under 35 U.S.C. 154(d)(4).								
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau).								
b. have been communicated by the International Bureau.								
c. have not been made; however, the time limit for making such amendments has NOT expired.								
d. have not been made a	d. have not been made and will not be made.							
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].								
9. An oath or declaration of the	2. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].							
Article 36 [35 U.S.C. 371(c)	(5)].	Preliminary Examination Report under PCT						
_	document(s) or information include	a:						
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment.								
14. An Application Data Sheet u								
5. A substitute specification.								
16. A power of attorney and/or change of address letter.								
7. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.								
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).								
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).								
20. Other items or information:								
	·							

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
The following fees are submitted:

1 U	12	579	U)	PCT/U	S2005/000951		21581YP	
The following	fees are	submitted:			· · · · · · · · · · · · · · · · · · ·		CALCULATIONS	PTO USE ONLY
21. A Basic national fee					\$300.00			
22. Examination fee (37 CFR 1.492(c))								
	If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)							
All other situations					\$200.00			
23. Search fee (37 CFR 1.492(b))								
	If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)							
					onal application to the USPT			
International Searchin	g Author	ity				\$100	\$100.00	
1					US and provided to the Office			
previously communicated to the US by the IB								
						21, 22 and 23=	\$600.00	
11 1	•		_		er over 100 sheets (excluding The fee is \$250 for each add			
paper or fraction	_	, ined in an e	rectronic ii	neurum).	The fee is \$250 for each add	ittoliai 30 sheets of		
Total Sheets	Extra	Sheets			dditional 50 or fraction to a whole number)	RATE		
- 100 =	0	/50	0	=	0.	X \$250.00	\$0.00	
Surcharge of \$130.0 priority date [37 CFF		_	ath or decl	aration la	ter than 30 months from the e	earliest claimed		
CLAIMS		NUMBER	FILED		NUMBER EXTRA	RATE		
Total Claims			37	- 20 =	17	X \$50.00	\$850.00	
Independent Claims			1	- 3 =	0	X \$200.00	\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360.00				
	7	TOTAL OF	ABOVE (CALCUI	ATIONS (SUBTOTAL)	=	\$1,450.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)].								
TOTAL NATIONAL FEE				LFEE =	\$1,450.00	<u> </u>		
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be								
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property. + TOTAL FEES ENCLOSED =						\$1,450.00		
							Amount to be refunded:	
							Amount to be	
					- 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10		charged:	
a. A checl	k in the	amount of S	§		to cover the above fees is	s enclosed.		
b. Please charge my Deposit Account No. 13-2755 in the amount of \$1,450.00 to cover the above fees. A duplicate copy of this sheet is enclosed.								
The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any								
overpayment to the Deposit Account No. <u>13-2755</u> . A duplicate copy of this sheet is enclosed.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.								
SEND ALL CO	RRESPO	ONDENCE	TO:					
Customer No	. 00021	0						
MERCK & CO.	INC	i				RI	\sim \sim	AL
Patent Department, RY60-30						of Cherk	etle	
P.O. Box 2000 SIGNATURE								
126 East Lincoln Avenue Rahway, New Jersey 07065-0970								
	, 0,					ilippe L. Durette		
DATE: July 11.	2006				N.	AME		
	PHONE #: (732) 594-4568				35,125			
				_	R	EGISTRATION N	IUMBER	

Page 2 of 2

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning "Submission United States Designated United States Designated "Submission United States Designated United States Designa

-AP20Rec'd PCT/PTO 11 JUL 2006

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	21581YP				
International Appln No.:	PCT/US2005/000951 12 January 2005				
International Filing Date:					
Priority Date:	16 January 2004				
Title:	NOVEL CRYSTALLINE SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR				
Inventors:	Russell R. Ferlita, Karl Hansen, Vicky K. Vydra, Yaling Wang, and Christopher M. Lindemann				

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT July 11, 2006

EXPRESS MAIL NO. EL 989585040 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY LOTEY CLUTTOWSKY DATE 7-11-06